Assessment report on *Salvia fruticosa* Mill., folium

Final

Based on Article 10a of Directive 2001/83/EC as amended (well-established use)

Based on Article 16d(1), Article 16f and Article 16h of Directive 2001/83/EC as amended (traditional use)

<table>
<thead>
<tr>
<th>Herbal substance(s) (binomial scientific name of the plant, including plant part)</th>
<th><em>Salvia fruticosa</em> Mill., folium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbal preparation(s)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Pharmaceutical form(s)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Rapporteur(s)</td>
<td>C. Cavaleiro</td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>I. Chinou</td>
</tr>
</tbody>
</table>
# Table of contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of contents</td>
<td>2</td>
</tr>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>1.1. Description of the herbal substance(s), herbal preparation(s) or</td>
<td>4</td>
</tr>
<tr>
<td>combinations thereof</td>
<td></td>
</tr>
<tr>
<td>1.2. Search and assessment methodology</td>
<td>5</td>
</tr>
<tr>
<td>2. Data on medicinal use</td>
<td>5</td>
</tr>
<tr>
<td>2.1. Information about products on the market</td>
<td>5</td>
</tr>
<tr>
<td>2.1.1. Information about products on the market in the EU/EEA Member</td>
<td>5</td>
</tr>
<tr>
<td>States</td>
<td></td>
</tr>
<tr>
<td>2.1.2. Information on products on the market outside the EU/EEA</td>
<td>6</td>
</tr>
<tr>
<td>2.2. Information on documented medicinal use and historical data from</td>
<td>6</td>
</tr>
<tr>
<td>literature</td>
<td></td>
</tr>
<tr>
<td>2.3. Overall conclusions on medicinal use</td>
<td>7</td>
</tr>
<tr>
<td>3. Non-Clinical Data</td>
<td>8</td>
</tr>
<tr>
<td>3.1. Overview of available pharmacological data regarding the herbal</td>
<td>8</td>
</tr>
<tr>
<td>substance(s), herbal preparation(s) and relevant constituents thereof</td>
<td></td>
</tr>
<tr>
<td>3.1.1. Primary pharmacodynamics</td>
<td>8</td>
</tr>
<tr>
<td>3.1.2. Secondary pharmacodynamics</td>
<td>9</td>
</tr>
<tr>
<td>3.1.3. Safety pharmacology</td>
<td>11</td>
</tr>
<tr>
<td>3.1.4. Pharmacodynamic interactions</td>
<td>11</td>
</tr>
<tr>
<td>3.1.5. Conclusions</td>
<td>11</td>
</tr>
<tr>
<td>3.2. Overview of available pharmacokinetic data regarding the herbal</td>
<td>11</td>
</tr>
<tr>
<td>substance(s), herbal preparation(s) and relevant constituents thereof</td>
<td></td>
</tr>
<tr>
<td>3.3. Overview of available toxicological data regarding the herbal</td>
<td>11</td>
</tr>
<tr>
<td>substance(s)/herbal preparation(s) and constituents thereof</td>
<td></td>
</tr>
<tr>
<td>3.3.1. Single dose toxicity</td>
<td>11</td>
</tr>
<tr>
<td>3.3.2. Repeat dose toxicity</td>
<td>11</td>
</tr>
<tr>
<td>3.3.3. Genotoxicity</td>
<td>12</td>
</tr>
<tr>
<td>3.3.4. Carcinogenicity</td>
<td>12</td>
</tr>
<tr>
<td>3.3.5. Reproductive and developmental toxicity</td>
<td>12</td>
</tr>
<tr>
<td>3.3.6. Local tolerance</td>
<td>12</td>
</tr>
<tr>
<td>3.3.7. Other special studies</td>
<td>12</td>
</tr>
<tr>
<td>3.3.8. Conclusions</td>
<td>12</td>
</tr>
<tr>
<td>3.4. Overall conclusions on non-clinical data</td>
<td>12</td>
</tr>
<tr>
<td>4. Clinical Data</td>
<td>13</td>
</tr>
<tr>
<td>4.1. Clinical pharmacology</td>
<td>13</td>
</tr>
<tr>
<td>4.1.1. Overview of pharmacodynamic data regarding the herbal substance</td>
<td>13</td>
</tr>
<tr>
<td>(s)/preparation(s) including data on relevant constituents</td>
<td></td>
</tr>
<tr>
<td>4.1.2. Overview of pharmacokinetic data regarding the herbal substance</td>
<td>13</td>
</tr>
<tr>
<td>(s)/preparation(s) including data on relevant constituents</td>
<td></td>
</tr>
<tr>
<td>4.2. Clinical efficacy</td>
<td>13</td>
</tr>
<tr>
<td>4.2.1. Dose response studies</td>
<td>13</td>
</tr>
<tr>
<td>4.2.2. Clinical studies (case studies and clinical trials)</td>
<td>13</td>
</tr>
<tr>
<td>4.3. Clinical studies in special populations (e.g. elderly and</td>
<td>13</td>
</tr>
<tr>
<td>children)</td>
<td></td>
</tr>
<tr>
<td>4.4. Overall conclusions on clinical pharmacology and efficacy</td>
<td>13</td>
</tr>
</tbody>
</table>
5. Clinical Safety/Pharmacovigilance ................................................................. 13
5.1. Overview of toxicological/safety data from clinical trials in humans ........... 13
5.2. Patient exposure .......................................................................................... 13
5.3. Adverse events, serious adverse events and deaths ...................................... 14
5.4. Laboratory findings ..................................................................................... 14
5.5. Safety in special populations and situations ................................................ 14
5.5.1. Use in children and adolescents ................................................................. 14
5.5.2. Contraindications .................................................................................... 14
5.5.3. Special warnings and precautions for use ................................................ 14
5.5.4. Drug interactions and other forms of interaction ....................................... 14
5.5.5. Fertility, pregnancy and lactation ............................................................... 14
5.5.6. Overdose .................................................................................................. 14
5.5.7. Effects on ability to drive or operate machinery or impairment of mental ability ...... 14
5.5.8. Safety in other special situations ............................................................... 14
5.6. Overall conclusions on clinical safety .......................................................... 14

6. Overall conclusions (benefit-risk assessment) ................................................. 15

Annex .................................................................................................................. 15
1. Introduction

1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof

- Herbal substance(s)

Salvia fruticosa folium consists of the whole or cut, dried leaves of Salvia fruticosa Mill. containing not less than 18 mL/kg or 12 mL/kg of essential oil in the whole or in the cut drug respectively (calculated with reference to the dried drug). (Ph. Eur. 8th Edition 2014 (8.2)).

Salvia fruticosa Mill. (syn. Salvia triloba L.f.) is an evergreen shrub growing up to 1 m. Flowers hermaphrodite, calyx not accrescent, upper lip of corolla more or less straight and gynostegium present. S. fruticosa is clearly differentiated from S. officinalis due its trifoliate ovate-lanceolate or ovate leaves with typical hairy or tomentose coverings. The leaf blade is about 8 to 50 mm long and 4 mm to 20 mm wide. The leaf is oval to oblong-lanceolate. The margin is finely crenate and wavy, though indistinctly due to strong pubescence on both pages. The base is obtuse and has sometimes one or two lobes more or less developed. Both pages are tomentose with grey pubescence on the upper side and strong white pubescence beneath. The veining is indistinct. The petiole is strongly tomentose pubescence white and measures about 1 mm in diameter (Goñalons, 1993).

Principal constituents of the herbal substance

The following constituents have been reported (Al-Kalaldeh et al., 2010; Dincer et al., 2012; El-Sayed et al., 2001; Shaiq Ali et al., 2000; Kaliora et al., 2014; Proença da Cunha & Roque, 2008; Gruenwald et al., 2000):

Volatile compounds: The essential oil isolated from leaves is predominately composed of oxygen containing monoterpenes [1,8-cineole (40-67%), camphor (2-25%), α- and β-thujone (<5,0%)], monoterpen and sesquiterpene hydrocarbons (camphene, myrcene, α-pinene, β-pinene, E-caryophyllene).

Flavonoids: including 7-O-glucosides and 7-O-glucuronides of apigenin, chrysoeriol, hispidulin, luteolin, 6-methyl luteolin, salvigenin, jaceosidin.

Phenolic acids: rosmarinic acid (1.0 to 2.5%)

Diterpenes: including carnosic acid and carnosol (0.5%)

Triterpenes: ursolic acid, oleanolic acid, etc.

Bitter constituents: picrosalvine

- Herbal preparation(s)

Comminuted herbal substance.

- Combinations of herbal substance(s) and/or herbal preparation(s) including a description of vitamin(s) and/or mineral(s) as ingredients of traditional combination herbal medicinal products assessed, where applicable.

Not applicable
1.2. Search and assessment methodology

Databases and other sources used to research available pharmaceutical, non-clinical and clinical data on *Salvia fruticosa* Mill. or its relevant constituents:

Relevant articles and references retrieved from databases

- PubMed. Search terms
  - *Salvia triloba*. Publication year: June 1968-January 2014 (28 publications were listed)
  - *Salvia fruticosa*. Publication year: March/April 1987-July 2014 (49 publications listed)
  - Greek sage: (8 relevant publications listed)

- ISI Web of Science. Search terms
  - *Salvia triloba*. Publication year: June 1968-January 2014 (28 publications listed)
  - *Salvia fruticosa*. Publication year: March/April 1987-July 2014 (49 publications listed)
  - Greek sage: (11 relevant publications listed)
  - Three-lobed sage (1 relevant publication)

- The Cochrane Library
  - *Salvia triloba*: no entries listed
  - *Salvia fruticosa*: no entries listed
  - Greek sage: no entries listed
  - Three-lobed sage: no entries listed

Book collections from the following libraries

- Biblioteca das Ciências da Saúde da Universidade de Coimbra
- Biblioteca Geral Universidade de Coimbra

Pharmacopoeias and monographs

Information on *Salvia fruticosa* Mill. was carefully analysed and only articles considered of relevance to this Assessment Report were selected.

2. Data on medicinal use

2.1. Information about products on the market

2.1.1. Information about products on the market in the EU/EEA Member States
Table 1: Overview of data obtained from marketed medicinal products

<table>
<thead>
<tr>
<th>Active substance</th>
<th>Indication</th>
<th>Pharmaceutical form</th>
<th>Regulatory Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comminuted herbal substance</td>
<td>Herbal medicinal product in increased secretion of sweat</td>
<td>Infusion for oral use as a tea. Not specified posology</td>
<td>Marketed in Denmark from 1996 to 2001</td>
</tr>
</tbody>
</table>

This overview is not exhaustive. It is provided for information only and reflects the situation at the time when it was established.

Information on relevant combination medicinal products marketed in the EU/EEA

Not applicable

Information on other products marketed in the EU/EEA (where relevant)

Not applicable

2.1.2. Information on products on the market outside the EU/EEA

Not applicable

2.2. Information on documented medicinal use and historical data from literature

Archaeological evidences support that Salvia fruticosa, concealed among the ancient authors under the general name "eleisphakon," has probably been used for medicinal purposes since 1400 B.C. However, translations mistakes of that term in the restrictive sense of the garden sage (S. officinalis L.) are probably related with the loss of reputation as a medicinal herb and with the assignment to S. officinalis of uses most likely attributed for S. fruticosa.

Salvia fruticosa is an endemic species of the Eastern Mediterranean basin, extending its native range from Sicily and Southern Italy, Cyrenaica, the Southern part of the Balkan Peninsula, Greece to West Syria. Furthermore, it is found as a naturalized plant in the Western Mediterranean region, especially in Spain and Portugal, where it was probably introduced by ancient navigators. In all these regions S. fruticosa has been used over time in traditional medicine practices (Rivera et al., 1994; Karousou et al., 2000).

A systematic inventory of the medicinal uses of Salvia fruticosa, abridging literature, was published by Rivera et al. (1994). Authors testify its traditional use in southern E.U. countries, particularly in Spain and Portugal: the infusion of the leaves is used at Madeira, Portugal for relieving headache (before 1990) and as a blood depurative recommended for circulatory troubles. In Spain, the infusions and decoctions of leaves or flowering shoots are reputed as stomachic (taken during two or nine consecutive days), blood depurative, recommended for circulatory troubles and as a tranquilizer. In other non EU Mediterranean countries the infusions or decoctions are used as carminative and stomachic and the juice is used for poor appetite. Application as a vulnerary and cicatrizing has also been recorded in Spain.

An ethno-pharmacological survey (Dokos et al., 2009) of endemic medicinal plants in the Paphos district of Cyprus reports other positive uses of Salvia fruticosa to help digestion - as herbal tea is
offered to help digestion after heavy meals and as hypoglycaemic for the beneficial effects on the pancreatic function experienced by diabetic patients that consume a daily drink of sage as a breakfast tea. Infusion is also mentioned to reduce coughs, colds, sore throats and tonsillitis. Effects against sweating, anti-diarrhoeic, antipyretic, spasmyloytic and tonic were often reported (Dokos et al., 2009).

Proença da Cunha et al. (2008) reports the topical use of the infusion (3 to 4 g/100 ml of water) as a mouthwash or gargle for relief of inflammations and infections of the mouth and throat or as washes, irrigations or cataplasms for relief of mucosal inflammations and infections. Consistently the ESCOP monograph of trilobed sage (2014) [quoting Stahl-Biskup (2008) and Benedum (2006)] also express the beneficial topical use of the infusion (3 g of dried drug in 125 ml of water as a mouthwash or gargle) for relief of inflammations and infections of the mouth and throat.

The ESCOP monograph [quoting Stahl-Biskup 2008; Böhme 2010] also reports the oral use of the infusion (1 to 1.5 g of dried drug in 150 ml of water, once or several times daily) for relief of digestive disorders such as dyspepsia.

Table 2: Overview of historical data

<table>
<thead>
<tr>
<th>Herbal preparation</th>
<th>Documented use / Traditional use</th>
<th>Pharmaceutical form</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Comminuted herbal substance</td>
<td>Digestive disorders Dyspepsia</td>
<td>Infusion or decoction for oral use as a tea. A cup after heavy meals. 1-1.5 g of dried drug as an infusion in 150 ml of water, once or several times daily</td>
<td>Rivera et al., 1994; Dokos et al., 2009; ESCOP 2014 (quoting Stahl-Biskup, 2008 and Böhme, 2010)</td>
</tr>
<tr>
<td></td>
<td>Inflammations and infections of the mouth and throat</td>
<td>Infusion, 3-4 g/100 ml of water as a mouthwash or gargle</td>
<td>ESCOP 2014 (quoting Stahl-Biskup, 2008 and Böhme, 2010); Proença da Cunha, 2008</td>
</tr>
<tr>
<td></td>
<td>Mucosal inflammations and infections</td>
<td>Infusion or decoction, 3 to 4 g/100 ml of water. Topical application as washes, irrigations or cataplasms.</td>
<td>Proença da Cunha, 2008</td>
</tr>
<tr>
<td></td>
<td>Headache relief</td>
<td>Infusion for oral use as a tea not specified posology</td>
<td>Rivera et al., 1994</td>
</tr>
<tr>
<td></td>
<td>Diuretic</td>
<td>Infusion or decoction for oral use as a tea not specified posology</td>
<td>Rivera et al., 1994</td>
</tr>
<tr>
<td></td>
<td>Tranquilizer</td>
<td>Infusion or decoction for oral use as a tea not specified posology</td>
<td>Rivera et al., 1994</td>
</tr>
<tr>
<td></td>
<td>Hypoglycaemic (beneficial effects, restoring pancreatic dysfunction)</td>
<td>Infusion for oral use as a tea. A cup at breakfast (daily) not specified posology</td>
<td>Dokos et al., 2009</td>
</tr>
</tbody>
</table>

2.3. Overall conclusions on medicinal use

From existing scientific data, it is clear the popularity of *Salvia fruticosa* (leaves) in the traditional medicines of several Mediterranean regions. However, the earliest literature (such as Rivera et al., 1994) only reports the indications of medicinal use, but does not report full data on strength, posology
and duration of use. This kind of information only could be found in books and monographs published after 2008, so unsuitable and insufficient to prove the circumstances of a long-standing traditional use in accordance with Directive 2004/24/EC (i.e. more than 30 years including at least 15 years within EU). It seems that the scarcity of complete specific and unequivocal historical information on the long term traditional medicinal usage of trilobed-sage is probably due to the fact that medicinal applications of *Salvia fruticosa* have been improperly included in the repertory of usages of *S. officinalis*.

### 3. Non-Clinical Data

#### 3.1. Overview of available pharmacological data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof

**3.1.1. Primary pharmacodynamics**

Several non-clinical studies have been conducted with extracts, essential oil and isolated constituents of *Salvia fruticosa* Mill. *in vivo* and *in vitro*.

In this section, were considered studies putatively related to the most consistent indications attributed to *Salvia fruticosa*, namely the relief of mucosal inflammations and infections of mouth and throat (by topical use of the infusions) and for relief of dyspepsia and digestive disorders.

**Anti-inflammatory activity**

El-Sayed *et al.* (2006) investigated, *in vivo*, the anti-inflammatory activity of *Salvia triloba* chloroform dry extract (yield: 6.75%), ethanol dry extract (yield: 4%), butanol dry extract (yield: 1%) and water fluid extract (yield: >20%). The chloroform extract, by oral administration in rats at 25 mg/kg b.w. showed the highest anti-inflammatory activity in acute and chronic inflammation: carrageenan-induced rat paw oedema was inhibited by 17% (p<0.01) compared to 47% by diclofenac at 10 mg/kg as positive control. In the cotton pellet granuloma assay, the chloroform extract inhibited chronic mean gain in pellet weight by 18 mg compared to 29 mg by diclofenac.

**Antimicrobial and antiviral activity**

Sokovic *et al.* (2002) tested the antifungal activity of the essential oil of *S. triloba*, 1,8-cineole and camphor against 13 fungal species (type cultures and isolates), such as *Aspergillus* sp., *Penicillium* sp., *Phomopsis*, *Alternaria*, *Microsporum* and *Epidermophyton* sp. Minimum inhibitory concentrations (MIC) and minimum fungicidal concentrations (MFC) were found to be, respectively: 5.0-15.0 μl/ml and 5.0-20.0 μl/ml for the essential oil, 4.0-9.0 μl/ml and 5.0-15.0 μl/ml for 1,8-cineole, and 3.0-5.0 μl/ml and 3.0-10.0 μl/ml for camphor.

Sivropoulou *et al.* (1997), using the disk diffusion assay in the essential oil of *S. fruticosa*, noticed that the essential oil was bactericidal against *Staphylococcus aureus* at 1/4000 dilution, while dilutions up to 1/10000 caused a considerable decrease in bacterial growth rates.

The essential oil of *S. fruticosa* and its main components exhibited virucidal activity against *Herpes simplex* virus 1 at a concentration of 0.2% inactivated 80% of infectious virus within 30 minutes and thujone at 0.1% inactivated 95%, whereas 1,8-cineole and camphor at 0.1% inactivated 35% and 0%, respectively (Sivropoulou *et al.*, 1997).

Al-Bakri *et al.* (2010) studied the antibacterial and antifungal activities of ethanol extracts of seven *Salvia* species, as well as of the hydro-distilled volatile oil of *S. triloba* against *Candida albicans*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and methicillin-resistant *S. aureus* (MRSA) in planktonic and biofilm cultures. Activity was assessed using the agar diffusion method and broth microdilution method for determination of minimal inhibitory concentration (MIC) value.
S. triloba ethanol extract exhibited the highest antimicrobial activity and was the only active against S. aureus (minimal biocidal concentration: 1.0 ± 0.35 mg/ml). The activity of S. triloba volatile oil was higher than that of the ethanol extract, both in the extent and spectrum. Both, S. triloba ethanol extract (2.5 μg/ml) and volatile oil (0.1%) demonstrated dose-dependent anti-adhesion activities against E. coli (66.7% and 76.0%, respectively), but no activity was observed against P. aeruginosa and C. albicans. The ethanol extract demonstrated anti-adhesive effect against S. aureus (60.9%) and one of the MRSA strains (37.2%).

**Spasmolytic activity**

Todorov et al. (1984) studied the effects on the tone and phasic contractile activity of isolated segments from guinea pig ileum in vivo of extracts isolated from Salvia officinalis, Salvia triloba and Salvia verbenaca. From three-lobed sage leaf a fluid extract (1:2, 70% ethanol), a decoction an infusion and fractions of these obtained by partitioning between benzene and water were prepared and tested. The decoction and the aqueous fraction from the infusion caused contraction of the smooth muscle preparation without affecting phasic contractions. The aqueous fraction of the decoction decreased the tone and caused relaxation. The fluid extract potentiated phasic activity but did not affect the tone. The infusion caused contraction of the intestinal segments and intensified phasic contractions. All the extracts inhibited contractions induced by acetylcholine (10-7 M), barium chloride (10-4 M), histamine (10-5 M) and serotonin (10-5 M) by 20-90%.

Table 3: Overview of the main non-clinical data/conclusions

<table>
<thead>
<tr>
<th>Herbal preparation tested</th>
<th>Posology</th>
<th>Experimental model</th>
<th>Reference</th>
<th>Main non-clinical conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>fluid extract (1:2, 70% ethanol)</td>
<td>In vitro tests</td>
<td>Todorov et al. (1984)</td>
<td>Spasmolytic activity</td>
<td></td>
</tr>
<tr>
<td>Decoction / infusion</td>
<td>In vitro tests</td>
<td>Todorov et al. (1984)</td>
<td>Spasmolytic activity</td>
<td></td>
</tr>
<tr>
<td>Essential oil</td>
<td>In vitro tests</td>
<td>Al-Bakri et al. (2010), Sivropoulou et al. (1997), Sokovic et al. (2002)</td>
<td>Antifungal and antibacterial activities; Antiadhesive effect against S. aureus and other MRSA</td>
<td></td>
</tr>
<tr>
<td>1,8-cineole</td>
<td>In vitro tests</td>
<td>Sokovic et al. (2002)</td>
<td>Antifungal activity</td>
<td></td>
</tr>
<tr>
<td>camphor</td>
<td>In vitro tests</td>
<td>Sokovic et al. (2002)</td>
<td>Antifungal activity</td>
<td></td>
</tr>
<tr>
<td>Chloroform dry extract (yield: 6.75%)</td>
<td>oral administration in rats at 25 mg/kg b.w.</td>
<td>In vivo carrageenan-induced rat paw oedema was inhibited</td>
<td>El-Sayed et al. (2006)</td>
<td>Anti-inflammatory</td>
</tr>
</tbody>
</table>

3.1.2. Secondary pharmacodynamics

**Antihypertensive activity**

Todorov et al. (1984) explored the antihypertensive activity of Salvia triloba using an in vivo rat model. A dry extract (decoction, DER not available), administered intraperitoneally to nembutal-anaesthetised,
spontaneously hypertensive rats as a single dose of 50 mg/kg b.w., reduced blood pressure by 31% compared to saline controls after 120 minutes.

Central Nervous System (CNS) effects

Todorov et al. (1984) studied the central effects of *Salvia fruticosa*. A dry decoction and the dry benzene fraction from an infusion and administered subcutaneously to mice at 100 mg/kg b.w. 10 minutes before administration of hexobarbital (80 mg/kg b.w.), delayed the onset of sleep. Relatively to sedative and hypnotic effects, compounds isolated from *S. triloba* prolonged hexobarbital sleep in the rat.

Orhan and Aslan (2009) showed that a 75% hydroethanolic dry extract (1g/60 ml; total phenolic content: 10.9 mg/g, expressed as gallic acid equivalent) exerted dose-dependent anti-amnesic activity in mice. A passive avoidance apparatus (step-through type) was used to investigate long-term memory; amnesia was induced by scopolamine (1 mg/kg, given intra-peritoneal 30 minutes after oral administration of the extract) and donepezil was used as a positive control. The extract had a relative memory-enhancing effect of 57.1 and 71.4% at 200 and 400 mg/kg b.w. respectively (control group 0%, donepezil group set to 100%).

Mahdy et al. (2012) studied the effect of *Salvia triloba* methanol extracts on the oxidative stress status in Alzheimer’s disease (AD) induced in rats. Seventy male rats were distributed into 7 groups: control group, AD induced rats (positive control), AD group treated with Rivastigmine in a dose of 0.3 mg/kg b.w.t., AD induced rats treated with total extract of *S. triloba* in a dose of 750 or 375 mg/kg b.w.t. After three months of exposure to this treatment oxidative stress markers, malondialdehyde (MDA) and nitric oxide (NO); total antioxidant capacity (TAC) and superoxide dismutase activities (SOD), acetylcholine (Ach) and acetylcholinesterase (AchE) were assessed. Both doses of Greek-sage extracts demonstrated significant increase in Ach (12.4% - *S. triloba*), serum TAC and SOD. Brain AchE, MDA and NO showed significant decrease in AD induced rats. *S. triloba* reduces the oxidative stress status and improves the neurodegeneration characteristic of Alzheimer’s disease in rats. *S. triloba* treatments inhibit AchE, retarding the catabolism of Ach, which have been shown to improve memory functions.

Salah and Jäger (2005) studied the *in vitro* inhibition of acetylcholinesterase, the affinity to the GABA A-benzodiazepine site and to the serotonin transporter of aqueous, ethanol and ethyl acetate extracts of *S. triloba* and other six plants traditionally used for treatment of neurological disorders. In what concerns to *S. triloba* the ethyl acetate extract showed a weak inhibitory activity by 28% at 1.0 mg/ml and 11% at 0.25 mg/ml, while a dry aqueous extract (1 g/20 ml) was inactive (Ellman’s method). Aqueous and ethanol extracts were tested for their binding affinity at the benzodiazepine site, an action that enhance the receptor sensitivity endogenous GABA. The aqueous extracts showed little effect, whereas the ethanolic extract of *S. triloba* has moderate activity. In what concerns to serotonin reuptake binding assay, results showed no significant activity.

Senol et al. (2010) studied the inhibition of acetylcholinesterase activity of a dichloromethane dry extract of *S. fruticosa* (13.4:1) to. Results showed 27% of inhibition at 25 μg/ml and 51% at 100 μg/ml.

Orhan et al. (2009) tested the potential of 75% hydro ethanol dry extract (1 g/60 ml; 1% total phenols) to inhibit acetylcholinesterase activity, obtaining an IC<sub>50</sub> of 0.71 mg/ml.

Savelev et al. (2004) assessed the inhibition of the human cholinesterases by *S. triloba* leaf essential oil. Results were inconsistent concerning to butyrylcholinesterase. However, IC<sub>50</sub> values of 0.04-0.06 mg/ML were reported regarding the inhibition of acetylcholinesterase. The major constituents of the essential oil were also tested individually. The most pronounced acetylcholinesterase inhibition was observed for 1,8-cineole (IC<sub>50</sub>: 0.06 mg/ml), β-caryophyllene.
(IC\textsubscript{50}: 0.03 mg/ml), α-pinene (IC\textsubscript{50}: 0.1 mg/ml) and β-pinene (IC\textsubscript{50}: 0.2 mg/ml); α-thujone and camphor at 0.5 mg/ml inhibited the enzyme by 37% and 13%, respectively. None or low butyrylcholinesterase inhibition was observed.

**Ulcerogenicity**

El-Sayed et al. (2006) studied *in vivo* the ulcerogenic potential of the oral administration to rats of 25 mg/kg b.w of several extracts of *Salvia triloba* [Chloroform (dry yield: 6.75%), ethanol (4%), butanol (1%) and water (>20%, viscous extract)]. The ulcer indices were 0 for the ethanol extract, 1.2 for the water extract (p<0.01) and 1.3 for the chloroform extract (p<0.01), compared to the positive control 12.3 (acetylsalicylic acid at 1 mg/kg).

**Oestrogenic activity**

There are reports of the oestrogenic activity of *Salvia* species (*S. officinalis*, *S. sclarea* and *S. lavandulae folia*) and some of them are components of preparations used to treat gynaecological disorders particularly in Spain (Duke, 1985). According Rivera et al., (1994) *S. fruticosa* may be in the origin of such reports.

### 3.1.3. Safety pharmacology

No data available.

### 3.1.4. Pharmacodynamic interactions

No data available.

### 3.1.5. Conclusions

Results of non-clinical pharmacological studies are compatible or not contradictory with the plausibility of the beneficial effects of *Salvia fruticosa* infusions or decoctions for relief of mucosal inflammations and infections and digestive spasms. These effects are probably related with the tannin content, as well as of the predominant volatile compounds, 1,8-cineole and camphor.

None of the reported results constitute any cause for safety concern.

### 3.2. Overview of available pharmacokinetic data regarding the herbal substance(s), herbal preparation(s) and relevant constituents thereof

No data available.

### 3.3. Overview of available toxicological data regarding the herbal substance(s)/herbal preparation(s) and constituents thereof

No data available.

### 3.3.1. Single dose toxicity

No data available.

### 3.3.2. Repeat dose toxicity

No data available.
3.3.3. Genotoxicity

No data available.

3.3.4. Carcinogenicity

No data available.

3.3.5. Reproductive and developmental toxicity

Elbetieha et al. (1998) studied the reproductive toxicity potential of *Salvia fruticosa* in rats. Ingestion of an aqueous dry extract by female rats at 200, 400 and 800 mg/kg b.w. from days 1 to day 6 of pregnancy had no significant effects on the number of pregnancies, implantations, viable fetuses or resorptions when compared to the control. Intragastric administration of a 95%-ethanolic dry extract at 400 mg/kg also had no effect on the number of pregnancies or implantations, but the number of viable fetuses decreased (p<0.005) and the number of resorptions increased (p<0.005). In contrast, intragastric administration of the aqueous dry extract at 800 mg/kg or the ethanolic dry extract at 400 mg/kg to adult female rats for 30 consecutive days had no effect on the occurrence of pregnancy, but the number of implantations (p<0.05) and viable fetuses (p<0.01) decreased and the number of resorptions increased (p<0.01 for aqueous dry extract, p<0.005 for ethanolic dry extract). Ingestion of the same extracts at the same dosage levels for 30 consecutive days by adult male rats had no effect on the final number of pregnant females impregnated by these males. On the other hand, the number of implantations and viable fetuses were reduced in such females (p<0.01 for aqueous dry extract, p<0.001 for ethanolic dry extract), whereas the number of resorptions increased (p<0.005). Prenatal exposure of male and female rat offspring to the ethanolic dry extract at 400 mg/kg showed no effect on the timing of testicular descent or vaginal opening.

3.3.6. Local tolerance

No data available.

3.3.7. Other special studies

α- and β-Thujones are known to be abortifacient and emmenagogic (Barnes et al., 2007).

3.3.8. Conclusions

Data are insufficient to state the safety of the use of *Salvia fruticosa* during pregnancy and lactation. Although the little concentration of α- and β-thujones expected in water extracts of *Salvia fruticosa* (relative amount of α- and β-thujones in the essential oil of *Salvia fruticosa* doesn't exceed 5.0%) reproductive and developmental toxicity of these compounds should not be neglected.

3.4. Overall conclusions on non-clinical data

Results from relevant experimental studies to support the proposed indications are very limited. The reported pharmacological effects are not considered contradictory to the traditional indications of use. Specific data on pharmacokinetics and interactions are not available. Non-clinical information on the safety is scarce.
As there is no information on reproductive and developmental toxicity, the use during pregnancy and lactation cannot be recommended.

Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

4. Clinical Data

4.1. Clinical pharmacology

4.1.1. Overview of pharmacodynamic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents

No data available.

4.1.2. Overview of pharmacokinetic data regarding the herbal substance(s)/preparation(s) including data on relevant constituents

No data available.

4.2. Clinical efficacy

No data available.

4.2.1. Dose response studies

No data available.

4.2.2. Clinical studies (case studies and clinical trials)

No data available.

4.3. Clinical studies in special populations (e.g. elderly and children)

No data available.

4.4. Overall conclusions on clinical pharmacology and efficacy

There are no data on clinical pharmacology or efficacy available for *Salvia fruticosa* to support a well-established use indication.

5. Clinical Safety/Pharmacovigilance

5.1. Overview of toxicological/safety data from clinical trials in humans

No data available.

5.2. Patient exposure

No data available.
5.3. Adverse events, serious adverse events and deaths

No data available.

5.4. Laboratory findings

No data available.

5.5. Safety in special populations and situations

No data available.

5.5.1. Use in children and adolescents

No data available to support safety in children and adolescents.

5.5.2. Contraindications

No data available.

5.5.3. Special warnings and precautions for use

No data available.

5.5.4. Drug interactions and other forms of interaction

No data available.

5.5.5. Fertility, pregnancy and lactation

No data available to support safety by the use of woman during pregnancy and lactation.

5.5.6. Overdose

No data available.

5.5.7. Effects on ability to drive or operate machinery or impairment of mental ability

No data available.

5.5.8. Safety in other special situations

No data available.

5.6. Overall conclusions on clinical safety

Conventional clinical safety data for Salvia fruticosa are absent.

Salvia fruticosa cannot be recommended for oral use in children and adolescents under 18 years of age due to lack of adequate data.
The use of *Salvia fruticosa* should not be recommended during pregnancy and lactation due to insufficient data. No data on fertility is available.

6. **Overall conclusions (benefit-risk assessment)**

There is no suitable documentation to support the long-standing use or the well-established use of *Salvia fruticosa*, folium as laid down in Article 16a(1)(e) or Article 10a of Directive 2001/83/EC, respectively.

There is some documentation that herbal preparations of the *Salvia fruticosa* folium are in medicinal use within the European Union for more than 15 years but less than 30 years. Information regarding the medicinal use outside the European Union for more than 30 years is also insufficient.

There are no clinical data supporting efficacy and safety and the experimental toxicological data are limited.

Genotoxicity, carcinogenicity, reproductive and developmental toxicology of *Salvia fruticosa* folium have not been evaluated.

In conclusion, the HMPC is of the opinion that a European Union herbal monograph on *Salvia fruticosa* folium cannot be established at present, unless new data are made available.

**Annex**

**List of references**